<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959189</url>
  </required_header>
  <id_info>
    <org_study_id>ERX-963-001</org_study_id>
    <nct_id>NCT03959189</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1</brief_title>
  <official_title>Double-Blind, Placebo-Controlled, Dose-Range-Finding, Crossover Trial of Single Day Administration of ERX-963 in Adults With Myotonic Dystrophy Type 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Expansion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Expansion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in this study will receive two treatments, placebo and ERX-963, on different&#xD;
      days in a randomized fashion.&#xD;
&#xD;
      The primary purpose of this study is to investigate the safety and tolerability of ERX-963 in&#xD;
      participants diagnosed with Myotonic Dystrophy, Type 1 (DM1).&#xD;
&#xD;
      The secondary purpose is to evaluate the potential of ERX-963 treatment to reduce excessive&#xD;
      daytime sleepiness / hypersomnia and improve cognitive function in DM1 participants compared&#xD;
      to placebo treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is evaluating single administration of two dose levels of ERX-963 to explore the&#xD;
      relationship between dose, safety, tolerability, exposure and clinical benefit. This is a&#xD;
      multi-center, randomized, double-blind, placebo-controlled, two-treatment period crossover&#xD;
      study in two cohorts of participants with DM1.&#xD;
&#xD;
      Participants who have consented and meet eligibility criteria will receive two treatments,&#xD;
      placebo and ERX-963, in a randomized crossover fashion with a washout period between the&#xD;
      treatments. On treatment days, participants will receive treatment followed by repeated blood&#xD;
      collection for pharmacokinetic analysis and administration of a battery of outcome measures&#xD;
      relevant to sleep and cognition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events, Serious Adverse Events, and Drug-related Adverse Events [Safety and Tolerability] After a Single Dose of ERX-963 vs. Placebo</measure>
    <time_frame>Adverse Events were collected from screening to the End of Study Visit, up to 57 days</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. Treatment-emergent AEs were AEs which started between the date and time of study drug dosing and through Study Day 2, within each period. Drug-related AEs were assessed by the investigator to determine the relationship (related or unrelated) between the study intervention and each AE occurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the Effect of ERX-963 on the Stanford Sleepiness Scale Score Compared to the Effect of Placebo</measure>
    <time_frame>From dosing to approximately 2 hours</time_frame>
    <description>Participants will self-report their level of sleepiness by self-rated questionnaire &quot;Stanford Sleepiness Scale&quot; (SSS). This is a single item questionnaire on a 7-point scale (1-7). Higher values indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Effect of ERX-963 on the Change in Patient Global Impression - Improvement Scale (PGI-I) Compared to Placebo</measure>
    <time_frame>Administered at the end of the dosing visit day, upon completion of the other outcome measures. Approximately 2 hours after the end of infusion.</time_frame>
    <description>The PGI-I is a 7-point rating system used by the patient to rate their overall clinical condition after intervention relative to before intervention where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse, and 7=very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Effect of ERX-963 on the Clinical Global Impressment - Improvement (CGI-I) Scale Compared to Placebo</measure>
    <time_frame>Administered at the end of the dosing visit day, upon completion of the other outcome measures. Approximately 2 hours after the end of infusion.</time_frame>
    <description>The CGI-I is a 7-point rating system used by the clinician or investigator to compare the patient's overall clinical condition after intervention relative to before intervention where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse, and 7=very much worse (Guy, 1976; Busner, 2007).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Effect of ERX-963 on the Psychomotor Vigilance Task (PVT)</measure>
    <time_frame>From dosing to approximately 2 hours</time_frame>
    <description>Participants will be tested for their response time and number of lapses during the PVT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Effect of ERX-963 on the One-back Task</measure>
    <time_frame>From dosing to approximately 2 hours</time_frame>
    <description>Participants will be tested for the proportion of correct response to the One-back task.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Myotonic Dystrophy, Type 1 (DM1)</condition>
  <condition>Myotonic Dystrophy</condition>
  <arm_group>
    <arm_group_label>ERX-963 then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then ERX-963</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive placebo followed by a washout period. After the washout period, participants will receive ERX-963.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERX-963</intervention_name>
    <description>Active medicine</description>
    <arm_group_label>ERX-963 then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparator</description>
    <arm_group_label>Placebo then ERX-963</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  18 to 65 years of age&#xD;
&#xD;
          -  DM1 defined by genetic testing or clinical-confirmation&#xD;
&#xD;
          -  Epworth Sleepiness Scale (ESS) of &gt; 11 or participants who have long sleep periods of&#xD;
             an average of &gt; 10 hours a day&#xD;
&#xD;
          -  Age of onset of DM1 greater than 16 years&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Significant respiratory compromise&#xD;
&#xD;
          -  Significant cardiac disease&#xD;
&#xD;
          -  Diagnosis of symptomatic Restless Leg Syndrome or significant untreated nocturnal&#xD;
             hypoxias&#xD;
&#xD;
          -  Significant moderate to severe hepatic insufficiency&#xD;
&#xD;
          -  Clinically active depression, anxiety, or other medical condition that, in the&#xD;
             investigator's opinion, would interfere with the safety and efficacy assessments&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  History of panic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Ehrich, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Neurosciences Health Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine Specialists of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Sleep &amp; Wake Disorders</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.expansionrx.com/</url>
    <description>Expansion Therapeutics Corporate Website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <results_first_submitted>January 11, 2021</results_first_submitted>
  <results_first_submitted_qc>June 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Excessive Daytime Sleepiness</keyword>
  <keyword>hypersomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03959189/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03959189/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between June 2019 and March 2020, 12 patients were enrolled and treated with ERX-963 at three sites in the United States (Stanford University Neurosciences Health Center, University of Iowa Hospitals and Clinics, and Sleep Specialists of South Florida).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: 1 mg ERX-963</title>
          <description>Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 1 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 1 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: 2 mg ERX-963</title>
          <description>Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: 1 mg ERX-963</title>
          <description>Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 1 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 1 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: 2 mg ERX-963</title>
          <description>Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" lower_limit="47" upper_limit="59"/>
                    <measurement group_id="B2" value="44.0" lower_limit="29" upper_limit="56"/>
                    <measurement group_id="B3" value="51.5" lower_limit="29" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events, Serious Adverse Events, and Drug-related Adverse Events [Safety and Tolerability] After a Single Dose of ERX-963 vs. Placebo</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. Treatment-emergent AEs were AEs which started between the date and time of study drug dosing and through Study Day 2, within each period. Drug-related AEs were assessed by the investigator to determine the relationship (related or unrelated) between the study intervention and each AE occurrence.</description>
        <time_frame>Adverse Events were collected from screening to the End of Study Visit, up to 57 days</time_frame>
        <population>The safety population is defined as all participants who sign the study-specific informed consent documents and received at least 1 dose of ERX-963 or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 1 mg ERX-963</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 1 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 1 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 2 mg ERX-963</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events, Serious Adverse Events, and Drug-related Adverse Events [Safety and Tolerability] After a Single Dose of ERX-963 vs. Placebo</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. Treatment-emergent AEs were AEs which started between the date and time of study drug dosing and through Study Day 2, within each period. Drug-related AEs were assessed by the investigator to determine the relationship (related or unrelated) between the study intervention and each AE occurrence.</description>
          <population>The safety population is defined as all participants who sign the study-specific informed consent documents and received at least 1 dose of ERX-963 or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related AEs in Placebo period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related AEs in ERX-963 period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs in Placebo period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs in ERX-963 period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Effect of ERX-963 on the Stanford Sleepiness Scale Score Compared to the Effect of Placebo</title>
        <description>Participants will self-report their level of sleepiness by self-rated questionnaire &quot;Stanford Sleepiness Scale&quot; (SSS). This is a single item questionnaire on a 7-point scale (1-7). Higher values indicate worse outcome.</description>
        <time_frame>From dosing to approximately 2 hours</time_frame>
        <population>All treated participants who completed all the protocol specified assessments in both treatment periods were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 1 mg ERX-963 Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 1 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 1 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: 2 mg ERX-963 Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Effect of ERX-963 on the Stanford Sleepiness Scale Score Compared to the Effect of Placebo</title>
          <description>Participants will self-report their level of sleepiness by self-rated questionnaire &quot;Stanford Sleepiness Scale&quot; (SSS). This is a single item questionnaire on a 7-point scale (1-7). Higher values indicate worse outcome.</description>
          <population>All treated participants who completed all the protocol specified assessments in both treatment periods were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline Stanford Sleepiness Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="0.79"/>
                    <measurement group_id="O2" value="3.4" spread="0.79"/>
                    <measurement group_id="O3" value="4.0" spread="2.12"/>
                    <measurement group_id="O4" value="4.2" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min. after end of infusion, SSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.82"/>
                    <measurement group_id="O2" value="2.7" spread="1.60"/>
                    <measurement group_id="O3" value="4.0" spread="1.87"/>
                    <measurement group_id="O4" value="3.8" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 min. after end of infusion, SSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.57"/>
                    <measurement group_id="O2" value="2.9" spread="1.68"/>
                    <measurement group_id="O3" value="4.2" spread="1.92"/>
                    <measurement group_id="O4" value="4.0" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr., 10 min. after end of infusion, SSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.98"/>
                    <measurement group_id="O2" value="3.1" spread="1.57"/>
                    <measurement group_id="O3" value="4.0" spread="1.73"/>
                    <measurement group_id="O4" value="5.0" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr., 40 min. after end of infusion, SSS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.40"/>
                    <measurement group_id="O2" value="3.3" spread="0.76"/>
                    <measurement group_id="O3" value="4.6" spread="1.82"/>
                    <measurement group_id="O4" value="5.6" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model will be used to compare SSS effects following ERX-963 versus placebo. In the primary analysis of SSS, the cohort 1 and cohort 2 data were combined for ERX-963 and placebo treatments.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7746</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>mixed effects model</param_type>
            <param_value>-0.0796</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2768</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model will be used to compare SSS effects following 1 mg ERX-963 versus placebo. In this analysis of SSS, the effect of 1 mg ERX-963 treatment was compared to the effect of placebo treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4700</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>mixed effects model</param_type>
            <param_value>-0.2608</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3589</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A mixed effects model will be used to compare SSS effects following 2 mg ERX-963 versus placebo. In this analysis of SSS, the effect of 2 mg ERX-963 treatment was compared to the effect of placebo treatment.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8127</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>mixed effects model</param_type>
            <param_value>0.1016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4272</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Effect of ERX-963 on the Change in Patient Global Impression - Improvement Scale (PGI-I) Compared to Placebo</title>
        <description>The PGI-I is a 7-point rating system used by the patient to rate their overall clinical condition after intervention relative to before intervention where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse, and 7=very much worse.</description>
        <time_frame>Administered at the end of the dosing visit day, upon completion of the other outcome measures. Approximately 2 hours after the end of infusion.</time_frame>
        <population>All treated participants who completed all the protocol specified assessments in both treatment periods were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 1 mg ERX-963 Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: 2 mg ERX-963 Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Effect of ERX-963 on the Change in Patient Global Impression - Improvement Scale (PGI-I) Compared to Placebo</title>
          <description>The PGI-I is a 7-point rating system used by the patient to rate their overall clinical condition after intervention relative to before intervention where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse, and 7=very much worse.</description>
          <population>All treated participants who completed all the protocol specified assessments in both treatment periods were analyzed.</population>
          <units>Score of a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.27"/>
                    <measurement group_id="O2" value="3.4" spread="1.13"/>
                    <measurement group_id="O3" value="4.0" spread="2.00"/>
                    <measurement group_id="O4" value="4.2" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Effect of ERX-963 on the Clinical Global Impressment - Improvement (CGI-I) Scale Compared to Placebo</title>
        <description>The CGI-I is a 7-point rating system used by the clinician or investigator to compare the patient's overall clinical condition after intervention relative to before intervention where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse, and 7=very much worse (Guy, 1976; Busner, 2007).</description>
        <time_frame>Administered at the end of the dosing visit day, upon completion of the other outcome measures. Approximately 2 hours after the end of infusion.</time_frame>
        <population>All treated participants who completed all the protocol specified assessments in both treatment periods were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: 1 mg ERX-963 Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: Placebo Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: 2 mg ERX-963 Period</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Effect of ERX-963 on the Clinical Global Impressment - Improvement (CGI-I) Scale Compared to Placebo</title>
          <description>The CGI-I is a 7-point rating system used by the clinician or investigator to compare the patient's overall clinical condition after intervention relative to before intervention where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse, and 7=very much worse (Guy, 1976; Busner, 2007).</description>
          <population>All treated participants who completed all the protocol specified assessments in both treatment periods were analyzed.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.25"/>
                    <measurement group_id="O2" value="3.9" spread="0.90"/>
                    <measurement group_id="O3" value="4.0" spread="1.22"/>
                    <measurement group_id="O4" value="4.4" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Effect of ERX-963 on the Psychomotor Vigilance Task (PVT)</title>
        <description>Participants will be tested for their response time and number of lapses during the PVT.</description>
        <time_frame>From dosing to approximately 2 hours</time_frame>
        <population>PVT analysis was not performed for this study as this outcome measure analysis requirement was removed in the amended statistical plan. At the end of the clinical study, the project was terminated and the development group was disbanded. The entire team that worked on this project departed and moved on to their new companies. Therefore, this Outcome Measure has zero total analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 1 mg ERX-963</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 1 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 1 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 2 mg ERX-963</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Effect of ERX-963 on the Psychomotor Vigilance Task (PVT)</title>
          <description>Participants will be tested for their response time and number of lapses during the PVT.</description>
          <population>PVT analysis was not performed for this study as this outcome measure analysis requirement was removed in the amended statistical plan. At the end of the clinical study, the project was terminated and the development group was disbanded. The entire team that worked on this project departed and moved on to their new companies. Therefore, this Outcome Measure has zero total analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Effect of ERX-963 on the One-back Task</title>
        <description>Participants will be tested for the proportion of correct response to the One-back task.</description>
        <time_frame>From dosing to approximately 2 hours</time_frame>
        <population>One-back task analysis was not performed for this study as this outcome measure analysis requirement was removed in the amended statistical plan. At the end of the clinical study, the project was terminated and the development group was disbanded. The entire team that worked on this project departed and moved on to their new companies. Therefore, this Outcome Measure has zero total analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: 1 mg ERX-963</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 1 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 1 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: 2 mg ERX-963</title>
            <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Effect of ERX-963 on the One-back Task</title>
          <description>Participants will be tested for the proportion of correct response to the One-back task.</description>
          <population>One-back task analysis was not performed for this study as this outcome measure analysis requirement was removed in the amended statistical plan. At the end of the clinical study, the project was terminated and the development group was disbanded. The entire team that worked on this project departed and moved on to their new companies. Therefore, this Outcome Measure has zero total analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from screening to the End of Study Visit, which was a period of up to 57 days</time_frame>
      <desc>The adverse event and serious adverse event definition for this study did not differ from the clinicaltrials.gov definitions.&#xD;
Treatment-emergent AEs were AEs which started between the date and time of study drug dosing and through Study Day 2, within each period.&#xD;
Drug-related AEs were assessed by the investigator to determine the relationship (related or unrelated) between the study intervention and each AE occurrence.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Placebo Period</title>
          <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: 1 mg ERX-963 Period</title>
          <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 1 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 1 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: Placebo Period</title>
          <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2: 2 mg ERX-963 Period</title>
          <description>The crossover design tests each subject under different treatment conditions allowing for each subject to serve as their own control.&#xD;
Sequence 1: Participants will receive placebo followed by a washout period. After the washout period, participants will receive 2 mg of ERX-963.&#xD;
Sequence 2: Participants will receive 2 mg of ERX-963 followed by a washout period. After the washout period, participants will receive placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Expansion Therapeutics reserves the right to embargo communications regarding trial results prior to public release for a period  60 days in order to protect patentable information. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed company confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The 0.5 mg dose level was not tested in this study.&#xD;
The analyses of the effect of ERX-963 on the Psychomotor Vigilance Task and the One-Back task were removed from the final analysis and documented accordingly in a Statistical Analysis Plan memo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Expansion Therapeutics, Inc.</organization>
      <phone>858-764-4290</phone>
      <email>info@expansionrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

